Donapati Jalander*, Kosika Sandeep, Kondapuram Parameshwar, B. Ramakrishna, Chindam Suresh
Gurunanak Institute of Technical Campus-School of Pharmacy, Ibrahimpatnam, Hyderabad, Telangana, India-501506
Department of Pharmacology, Gurunanak Institute of Techinical Campus-School Of Pharmacy, Ibrahimpatnam, Hyderabad, Telangana, India-501506
Objective: The primary objective of this study was to demonstrate that nebivolol–amlodipine combination therapy is superior to atenolol-amlodipine combination therapy with respect to mean fall in systolic blood pressure (SBP) and diastolic blood pressure (DBP). The secondary objective was to compare the response rate and to evaluate the tolerability of study medications between two treatment groups. Materials and methods: The two treatment groups were similar with respect to demographic characteristics. For data analysis, the whole population was divided into 2 subgroups, escalated patients and non-escalated patients. A total of 190 eligible patients (Nebivolol/Amlodipine combination therapy: 94; Atenolol/Amlodipine: 96) satisfying inclusion/exclusion criteria were enrolled on the study. This study was carried out at Syncorp Clinicare Technologies private Ltd, during the period of eight months from Jan 2013 to Aug 2013 in the academic year 2011-2013. Results and conclusion: The results of our study conﬁrmed that the combination therapy with Nebivolol /amlodipine is superior to atenolol/Amlodipine combination therapy in patients with mild-to-moderate essential hypertension. In conclusion, our study has shown that once daily treatment with Nebivolol /amlodipine offers superior antihypertensive efficacy over atenolol/Amlodipine combination therapy in patients with mild-to-moderate essential hypertension.
Keywords: Nebivolol, amlodipine, atenolol, heart, hypertension